Dalbavancin® Injectable Information for NH Prescribers

Dalbavancin information also available on Firstline (app.firstline.org)

NH Formulary Status: Formulary Restricted

Indication: Restricted to treatment of adults with:

1. Confirmed MRSA skin and soft tissue infections; AND
2. Oral anti-MRSA agents are not an option; AND
3. Outpatient use OR inpatient use if dalbavancin allows earlier hospital discharge; AND
4. Intended treatment duration is 1 week or more; AND
5. Patient is unable to receive IV vancomycin or daptomycin due to logistical barriers.

Dose Strategies	
Full dose option 1	1500 mg IV x 1 dose
Full dose option 2	1000 mg IV x 1 dose, then 500 mg IV x 1 dose, 1 week later
CrCl greater than or equal to 30 mL/min	no dose adjustment
CrCl less than 30 mL/min but *not on regular hemodialysis:*	a) 1000 mg IV x 1 dose **OR** b) 750 mg IV x 1 dose then 375 mg IV x 1 dose, 1 week later
Hemodialysis*:	a) 1500 mg IV x 1 dose **OR** b) 1000 mg IV x 1 dose then 500 mg IV x 1 dose, 1 week later *Can be dosed without regard to timing of hemodialysis
Mild hepatic impairment (Child-Pugh Class A)	Give full dose; no dose adjustment required
Moderate to severe hepatic impairment (Child-Pugh Class B or C)	No data available to determine the appropriate dosing

Note: Therapeutic drug monitoring is NOT necessary.

Adverse Effects:

- Most common: **nausea** (4.7%), **headache** (3.8%) and **diarrhea** (3.4%)
- Serious hypersensitivity reactions (anaphylaxis/anaphylactoid) and skin reactions have been reported. Allergic cross-reactivity with other glycopeptides (e.g. vancomycin) is possible.
- Less than 2% risk of hepatotoxicity and blood dyscrasias (anemia, eosinophilia, leucopenia, neutropenia, thrombocytopenia, thrombocythemia)
- Rapid IV infusion can result in infusion reactions/flushing syndrome

Additional Info:

- The safety and efficacy in pediatric patients (less than 18 years) has not been established
- Dalbavancin has a long half-life (8.5 days), allowing for once weekly dosing, *however* patients should still have a post dose follow up to evaluate for clinical response

Note: This is a brief note for Dalbavancin use and not intended to be a comprehensive summary